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Abstract
The 2007 M. Jeang Retrovirology Prize has been awarded to Dr. Karen L. Beemon
The Retrovirology Prize, awarded annually, recognizes an
outstanding mid-career retrovirologist aged 45 to 60 [1,2].
The prize, supported by the Ming K. Jeang Foundation,
alternates between HIV and non-HIV research. In 2005,
Dr. Stephen P. Goff was the prize winner [3]; and last year,
Dr. Joseph G. Sodroski was recognized for his HIV
research [4]. The 2007 awardee of the Retrovirology prize is
Dr. Karen L. Beemon  (Figure 1).
Dr. Beemon is Professor and Chair of the Biology Depart-
ment, Johns Hopkins University. Dr. Beemon received her
PhD in 1974 from the University of California, Berkeley,
working with Peter Duesberg. She was a postdoctoral fel-
low at the Salk Institute, working with Tony Hunter. She
was among the first to develop and apply molecular tech-
niques to characterize the genomes of RNA viruses,
describe recombination between viral genomes, charac-
terize sarcoma-specific sequences, and perform structure-
function analysis of Src proteins. Of particular impor-
tance, was her discovery that transformation mechanisms
of multiple classes of retroviruses involve aberrant phos-
phorylation of cellular proteins at tyrosine residues. Over
the last two decades, Dr. Beemon has contributed signifi-
cantly to the scientific community's understanding of the
role of cis-acting regulatory elements in regulation of RNA
splicing, polyadenylation, nuclear export and nonsense-
mediated RNA decay. Her work has consistently provided
a bridge to connect fundamental knowledge of RNA biol-
ogy to the field of retrovirology. Furthermore, Dr. Bee-
mon's work has revealed the contribution of post-
transcriptional gene regulation to viral oncogenesis. Her
present studies of insertional events in avian retroviruses
are identifying additional new mechanisms that contrib-
ute to cancer including activation of microRNA and ele-
vated telomerase expression.
KBL: How did you get interested in retroviruses – was it
the vantage point of virology, cell biology, or perhaps the
exciting potential of molecular techniques...?
KB: Actually, I wanted to work on messenger RNAs while in
graduate school. Since there were not good molecular tech-
niques for specific cellular mRNA analysis at that time, I
decided to work on viral RNA instead. Since retroviral pack-
aged genomic RNA is identical to one of the viral mRNAs, the
virus helped purify the mRNA for further study. Of course, first
we had to characterize the genome. I eventually was able to con-
centrate on viral mRNA after I got my job at Hopkins.
KBL: Your early research experiences were with well
known pioneers of the RNA tumor virus field. What les-
sons did you learn from them?
KB: My first research mentor at UC Berkeley was Harry Rubin.
I learned how to do tissue culture and assays for transformation
by Rous sarcoma virus in his lab. I was not very happy with my
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projects, however, and eventually left his lab and dropped out of
graduate school for nearly a year. After travelling and working,
I was motivated to go back to graduate school. When I went
back, I switched to the lab of Peter Duesberg, where I began
working with viral RNA for the first time. We were collaborat-
ing with Peter Vogt in trying to determine the complexity of the
genome of Rous sarcoma virus. Once we showed that the entire
genome was present in one RNA subunit, we started mapping
genes, showing that the oncogene src was at the 3' end near the
poly(A) sequence. Every 6 weeks or so, we would have joint lab
meetings with Peter Vogt's lab at USC, as well as the lab of
Michael Bishop and Harold Varmus at UCSF. This was a very
exciting time to be working on Rous sarcoma virus and studying
the mechanism of viral transformation. Peter Duesberg taught
me to pick important problems and to use the best techniques
available. He also taught me not to always believe dogma. I
moved to the Salk Institute for my postdoc to work with a new
PI named Tony Hunter, who allowed me to bring my own
research project with me. I was interested in determining the
product of the src gene and its mechanism of action. Tony
taught me to pay attention to details-that is how he discovered
tyrosine phosphorylation. The Salk had a very interactive group
of tumor virologists at that time, working with murine leukemia
viruses. We also started annual retrovirology meetings with the
Fred Hutchinson Cancer Center.
KBL: Your research program remained focused on chicken
retroviruses during the progression of many molecular
biologists to human retrovirus research. What would you
say regarding the scientific funding arena and trend for
funding agencies to bypass basic investigations in lieu of
"translational" research that more rapidly may move from
bench to bedside?
KB: I actually worked on a lentivirus, Visna, while in graduate
school-showing that its genomic complexity was the same as
that of the RNA tumor viruses. Later, at Hopkins I did some
work on HIV-1 splicing, but the general principles found were
similar to those previously determined for RSV. I have tried to
work on basic questions that were common to all of the retrovi-
ruses, such as characterization of the genome and of unspliced
RNA. It made sense to me to work with the simplest virus that
could give you the answer. I kept finding new questions to try to
answer with these viruses, so it didn't seem to make sense to
move to a more complex virus until we better understood the
simpler viruses. Also, I am interested in how viruses induce can-
cer.
Since I have mainly undergraduate and graduate students in
my lab, it seemed that chicken viruses would be safer for them
to work on than HIV-1. Finally, I enjoy being able to do some-
thing a little different than everyone else-so that it is not just a
race.
I am very disturbed by the current funding climate in which
basic science is deemed of lower priority than translational
research. Basic research with chicken and other animal viruses
led to the discoveries of oncogenes and their mechanism of
action. This led to the generation of many drugs currently used
in humans, including Gleevec. I think simple systems are much
more cost-effective and allow more innovation, resulting in rad-
ical changes in therapies. I think a lot of translational research
is fairly conservative and does not bring major breakthroughs.
KBL: You have been repeatedly successful in bringing fun-
damental questions in RNA biology to bear on retrovirus
replication and tumorigenesis. What is your advice to
aspiring scientists who also seek challenging cross disci-
plinary work?
KB: I have really enjoyed being at the interface of the RNA and
retrovirus fields, especially when the viral RNA behaved differ-
ently than predicted by those studying cellular mRNAs. Many
of the important discoveries in RNA biology were made by study
of viral RNA. The only disadvantage is you have to go to twice
as many meetings to keep up with both fields. Also, you have to
get used to having your session at the Retroviruses meeting on
Sunday morning.
KBL: What is currently the most exciting research in your
laboratory?
KB: I am tremendously excited about microRNAs. They seem to
play a huge role in oncogenesis, as well as normal development.
We currently are studying targets of miR-155, which is acti-
vated by ALV promoter insertion in B-cell lymphomas and is
up-regulated in many human tumors. Incredibly, this 22 nt
RNA is also critical for development of the immune system and
inflammatory responses, and even has a homolog in KSHV.
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KBL: Your career progression recently evolved to include
administration as the first woman to chair the oldest Biol-
ogy department in the country, which was founded in
1876. Why did you make this change and what is your
advice to those considering balancing research and
administrative career tracks?
KB: I wanted to be able to shape the direction of the depart-
ment. In addition, I felt that it was my turn to help administer
the department. However, it is very time-consuming and I am
glad that I did not take it on earlier in my career.
KBL: Would do you see as your role in mentoring junior
faculty and supporting the career development of senior
faculty?
KB: I have tried to integrate new junior faculty into the larger
Hopkins community so that they would not be isolated scientif-
ically. To this end, I have proposed joint appointments with
departments and graduate programs in the School of Medicine.
I have also nominated junior faculty to speak at the Cold Spring
Harbor Symposium, as well as for various awards. I have also
tried to integrate them, gradually, into the service work of the
department. Our junior faculty have also developed their own
mentoring system and read each other's papers, grants, and pro-
motion packages. I am also trying to develop some Centers to
bring people from different schools together. I also encourage
junior faculty to attend meetings, write more papers, and help
to make the department stronger.
Regarding senior faculty, the challenge is how to use each per-
son's talents most effectively. Some senior faculty would prefer
to do research full-time (or part-time) and others would prefer
to teach full-time. I am trying to develop mechanisms so this
can happen to enhance the careers of the faculty, as well as the
overall research and teaching missions of our department.
When I hire new faculty, I am looking for people who love to do
research and to teach, but this can change over time. I am also
trying to increase the diversity of the department at all levels.
KBL: Academe has been charged as training too many
PhDs. What changes do you feel important for training
the next generation of successful scientists?
KB: We need to educate our students about careers in addition
to academia. However, so far it seems that most of our students
are using their Ph.D. training, so it is not clear to me that there
are too many Biology Ph.Ds.
KBL: You represent a small cadre of woman who have
been promoted to the highest ranks of academe. You have
balanced your outstanding research career, administrative
service, and an active family life. What is your perspective
on the issue of work-life balance?
KB: I am very happy that I was able to have two daughters and
a scientific career. For this to work well, I think it is important
to have a supportive spouse. Nicole was born while I was a post-
doc and told by one PI that I was not allowed to work in the lab
while pregnant. However, I ignored him and kept on working
without problem. I think that an academic career allows one
great flexibility, which is important when you have children. I
think that having a family brings some balance to life and also
helps in mentoring students. I am very proud of my daughters,
even though they are not pursuing careers in science.
KBL: In years to come, how would you like to be remem-
bered?
KB: She loved being a scientist and a mother.
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